ARTICLE | Product Development
Accelerating the Accelerator
How J&Js plans to intercept COPD, gestational diabetes, HPV-driven cancer
March 28, 2016 7:00 AM UTC
One year out from the launch of its Disease Interception Accelerator, Janssen Research & Development LLC is rapidly developing new insights into how to study the transition from health to disease. Two of the group's newest disease ventures are starting by mining repositories of longitudinal data and biological samples to study how gestational diabetes and chronic obstructive pulmonary disease begin.
"We will go where the longitudinal data exist, and then revalidate in other populations," said Benjamin Wiegand, global head of the Disease Interception Accelerator (DIA)...